Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1989 Feb;83(2):698–707. doi: 10.1172/JCI113934

Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema.

J Jackson 1, R B Sim 1, K Whaley 1, C Feighery 1
PMCID: PMC303731  PMID: 2536404

Abstract

C1-inhibitor (C1-Inh) is an important inhibitor of the inflammatory response and deficiency of this inhibitor, which may be hereditary or acquired, is associated with recurrent episodes of edema. Recently, an autoimmune form of angioedema has been described that is associated with functional deficiency of C1-Inh and an autoantibody that impedes C1-Inh function. In this report we describe the isolation of C1-Inh from the monocytes and plasma of a patient with autoimmune angioedema and demonstrate that the patient's monocytes secrete structurally and functionally normal C1-Inh, but show that this protein circulates in the patient's plasma in an inactive, structurally altered form. Furthermore, using analytic gel electrophoresis techniques it is demonstrated that the patient's autoantibody facilitates cleavage of normal C1-Inh, by its target proteases, to the same species of C1-Inh that is found circulating in the patient's plasma. This autoantibody facilitated cleavage of normal C1-Inh is apparently a consequence of destabilization of protease/inhibitor complexes. These findings contribute to our understanding of protease/C1-Inh interactions and document important observations on pathogenic mechanisms in autoimmune disease.

Full text

PDF
698

Images in this article

701Image
on p.701
701Image
on p.701
701Image
on p.701
702Image
on p.702
702Image
on p.702
703Image
on p.703
704Image
on p.704
704Image
on p.704

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alsenz J., Bork K., Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med. 1987 May 28;316(22):1360–1366. doi: 10.1056/NEJM198705283162202. [DOI] [PubMed] [Google Scholar]
  2. Arlaud G. J., Sim R. B., Duplaa A. M., Colomb M. G. Differential elution of Clq, Clr and Cls from human Cl bound to immune aggregates. Use in the rapid purification of Cl subcomponents. Mol Immunol. 1979 Jul;16(7):445–450. doi: 10.1016/0161-5890(79)90069-5. [DOI] [PubMed] [Google Scholar]
  3. Bock S. C., Skriver K., Nielsen E., Thøgersen H. C., Wiman B., Donaldson V. H., Eddy R. L., Marrinan J., Radziejewska E., Huber R. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry. 1986 Jul 29;25(15):4292–4301. doi: 10.1021/bi00363a018. [DOI] [PubMed] [Google Scholar]
  4. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  5. Donaldson V. H., Harrison R. A., Rosen F. S., Bing D. H., Kindness G., Canar J., Wagner C. J., Awad S. Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies. J Clin Invest. 1985 Jan;75(1):124–132. doi: 10.1172/JCI111664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Donaldson V. H. The challenge of hereditary angioneurotic edema. N Engl J Med. 1983 May 5;308(18):1094–1095. doi: 10.1056/NEJM198305053081810. [DOI] [PubMed] [Google Scholar]
  7. Frank M. M., Gelfand J. A., Atkinson J. P. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976 May;84(5):580–593. doi: 10.7326/0003-4819-84-5-580. [DOI] [PubMed] [Google Scholar]
  8. Frank M. M. The C1 esterase inhibitor and hereditary angioedema. J Clin Immunol. 1982 Apr;2(2):65–68. doi: 10.1007/BF00916888. [DOI] [PubMed] [Google Scholar]
  9. Geha R. S., Quinti I., Austen K. F., Cicardi M., Sheffer A., Rosen F. S. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N Engl J Med. 1985 Feb 28;312(9):534–540. doi: 10.1056/NEJM198502283120902. [DOI] [PubMed] [Google Scholar]
  10. Gigli I., Porter R. R., Sim R. B. The unactivated form of the first component of human complement, C1. Biochem J. 1976 Sep 1;157(3):541–548. doi: 10.1042/bj1570541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gigli I., Ruddy S., Austen K. F. The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol. 1968 Jun;100(6):1154–1164. [PubMed] [Google Scholar]
  12. Hamilton A. O., Jones L., Morrison L., Whaley K. Modulation of monocyte complement synthesis by interferons. Biochem J. 1987 Mar 15;242(3):809–815. doi: 10.1042/bj2420809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Harpel P. C., Cooper N. R. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest. 1975 Mar;55(3):593–604. doi: 10.1172/JCI107967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Harrison R. A. Human C1 inhibitor: improved isolation and preliminary structural characterization. Biochemistry. 1983 Oct 11;22(21):5001–5007. doi: 10.1021/bi00290a019. [DOI] [PubMed] [Google Scholar]
  15. Jackson J., Sim R. B., Whelan A., Feighery C. An IgG autoantibody which inactivates C1-inhibitor. Nature. 1986 Oct 23;323(6090):722–724. doi: 10.1038/323722a0. [DOI] [PubMed] [Google Scholar]
  16. Johnson A. M., Alper C. A., Rosen F. S., Craig J. M. C1 inhibitor: evidence for decreased hepatic synthesis in hereditary angioneurotic edema. Science. 1971 Aug 6;173(3996):553–554. doi: 10.1126/science.173.3996.553. [DOI] [PubMed] [Google Scholar]
  17. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  18. Lappin D., Hamilton A. D., Morrison L., Aref M., Whaley K. Synthesis of complement components (C3, C2, B and C1-inhibitor) and lysozyme by human monocytes and macrophages. J Clin Lab Immunol. 1986 Jul;20(3):101–105. [PubMed] [Google Scholar]
  19. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984 Aug 15;177(3):531–557. [PubMed] [Google Scholar]
  20. Mogensen C. E. The glomerular permeability determined by dextran clearance using Sephadex gel filtration. Scand J Clin Lab Invest. 1968;21(1):77–82. doi: 10.3109/00365516809076979. [DOI] [PubMed] [Google Scholar]
  21. Nilsson T., Sjöholm I., Wiman B. Structural and circular-dichroism studies on the interaction between human C1-esterase inhibitor and C1s. Biochem J. 1983 Sep 1;213(3):617–624. doi: 10.1042/bj2130617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pensky J., Schwick H. G. Human serum inhibitor of C'1 esterase: identity with alpha-2-neuraminoglycoprotein. Science. 1969 Feb 14;163(3868):698–699. doi: 10.1126/science.163.3868.698. [DOI] [PubMed] [Google Scholar]
  23. Salvesen G. S., Catanese J. J., Kress L. F., Travis J. Primary structure of the reactive site of human C1-inhibitor. J Biol Chem. 1985 Feb 25;260(4):2432–2436. [PubMed] [Google Scholar]
  24. Schapira M., Silver L. D., Scott C. F., Schmaier A. H., Prograis L. J., Jr, Curd J. G., Colman R. W. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med. 1983 May 5;308(18):1050–1053. doi: 10.1056/NEJM198305053081802. [DOI] [PubMed] [Google Scholar]
  25. Sheffer A. L., Austen K. F., Rosen F. S., Fearon D. T. Acquired deficiency of the inhibitor of the first component of complement: report of five additional cases with commentary on the syndrome. J Allergy Clin Immunol. 1985 Jun;75(6):640–646. doi: 10.1016/0091-6749(85)90087-9. [DOI] [PubMed] [Google Scholar]
  26. Sim R. B., Reboul A. Preparation and properties of human C1 inhibitor. Methods Enzymol. 1981;80(Pt 100):43–54. doi: 10.1016/s0076-6879(81)80007-9. [DOI] [PubMed] [Google Scholar]
  27. Sim R. B. The human complement system serine proteases C1r and C1s and their proenzymes. Methods Enzymol. 1981;80(Pt 100):26–42. doi: 10.1016/s0076-6879(81)80006-7. [DOI] [PubMed] [Google Scholar]
  28. Tosi M., Duponchel C., Bourgarel P., Colomb M., Meo T. Molecular cloning of human C1 inhibitor: sequence homologies with alpha 1-antitrypsin and other members of the serpins superfamily. Gene. 1986;42(3):265–272. doi: 10.1016/0378-1119(86)90230-1. [DOI] [PubMed] [Google Scholar]
  29. Travis J., Salvesen G. S. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983;52:655–709. doi: 10.1146/annurev.bi.52.070183.003255. [DOI] [PubMed] [Google Scholar]
  30. Weiss R., Silverberg M., Kaplan A. P. The effect of C1 inhibitor upon Hageman factor autoactivation. Blood. 1986 Jul;68(1):239–243. [PubMed] [Google Scholar]
  31. Weiss V., Engel J. Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement. Hoppe Seylers Z Physiol Chem. 1983 Mar;364(3):295–301. [PubMed] [Google Scholar]
  32. Yeung Laiwah A. C., Jones L., Hamilton A. O., Whaley K. Complement-subcomponent-C1-inhibitor synthesis by human monocytes. Biochem J. 1985 Feb 15;226(1):199–205. doi: 10.1042/bj2260199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Zuraw B. L., Curd J. G. Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. J Clin Invest. 1986 Aug;78(2):567–575. doi: 10.1172/JCI112610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. de Agostini A., Schapira M., Wachtfogel Y. T., Colman R. W., Carrel S. Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody. Proc Natl Acad Sci U S A. 1985 Aug;82(15):5190–5193. doi: 10.1073/pnas.82.15.5190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. van der Graaf F., Koedam J. A., Griffin J. H., Bouma B. N. Interaction of human plasma kallikrein and its light chain with C1 inhibitor. Biochemistry. 1983 Sep 27;22(20):4860–4866. doi: 10.1021/bi00289a037. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES